Table 3.
Treatment and complications during hospitalization.
| Variable | Absolute frequency (%) | N |
|---|---|---|
| Antimicrobial therapy | ||
| Hydroxychloroquine | 12915 (85.6%) | 15084 |
| Lopinavir/Ritonavir (LPV/r) | 9254 (61.4%) | 15072 |
| Azithromycin | 9146 (60.8%) | 15036 |
| Beta-lactam antibiotics | 10795 (71.7%) | 15050 |
| Remdesivir | 68 (0.5%) | 14968 |
| Immunomodulatory therapy | ||
| Systemic corticosteroids | 5287 (35.2%) | 15034 |
| Interferon Beta-1B (IFNb) | 1689 (11.3%) | 15008 |
| Tocilizumab | 1276 (8.5%) | 15038 |
| Anakinra | 91 (0.6%) | 14939 |
| Immunoglobulin | 70 (0.5%) | 14821 |
| Ventilatory support | ||
| High flow nasal cannula | 1197 (8.0%) | 14989 |
| Invasive mechanical ventilation (IMV) | 998 (6.6%) | 15057 |
| Non-invasive mechanical ventilation (NIMV) | 733 (4.9%) | 15051 |
| Anticoagulant therapy | ||
| Low-molecular-weight heparin during hospitalization | 15016 | |
| No | 2645 (17.6%) | |
| Low (prophylactic) dose | 9713 (64.7%) | |
| High (anticoagulant) dose | 1648 (11%) | |
| Intermediate dose | 1010 (6.7%) | |
| Complications | ||
| Acute respiratory distress syndrome (ARDS) | 15057 | |
| No | 10077 (66.9%) | |
| Mild | 1203 (8.0%) | |
| Moderate | 1097 (7.3%) | |
| Severe | 2680 (17.8%) | |
| Bacterial pneumonia | 1680 (11.1%) | 15075 |
| Sepsis | 937 (6.2%) | 15080 |
| Intensive Care Unit admission | 1255 (8.3%) | 15129 |
| Outcome | ||
| Discharge | 11928 (78.8%) | 15140 |
| Death | 3181 (21.0%) | 15140 |
| Readmission | 573 (3.9%) | 14709 |
| Not discharged at the end of follow-up (after readmission) | 31 (0.2%) | 15140 |